Synopsis
Synopsis
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Erbumine, Perindopril
2. Perindopril
3. Perstarium
4. Pirindopril
5. S 9490
6. S 9490 3
7. S 9490-3
8. S 94903
9. S-9490
10. S9490
1. 107133-36-8
2. Aceon
3. Perindopril Tert-butylamine
4. Mcn-a-2833-109
5. Perindopril Erbumine [usan]
6. Perindopril (erbumine)
7. Pederindopril
8. S-9490-3
9. Chebi:8025
10. Nsc-758929
11. Perindopril T-butylamine Salt
12. (2s,3as,7as)-1-((s)-n-((s)-1-carboxybutyl)alanyl)hexahydro-2-indolinecarboxylic Acid, 1-ethyl Ester, Compound With Tert-butylamine (1:1)
13. 1964x464oj
14. (2s,3as,7as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic Acid;2-methylpropan-2-amine
15. S9490-3
16. Covapril
17. Coversyl
18. Unii-1964x464oj
19. Mfcd02313824
20. Aceon (tn)
21. Perindoprilerbumine
22. Dsstox_cid_24198
23. Dsstox_gsid_44198
24. Schembl41679
25. Spectrum1505212
26. Perindopril T-butylamine
27. Chembl1200343
28. Dtxsid1044198
29. Hy-b0130a
30. Perindopril Erbumine (jan/usp)
31. Amy3408
32. Hms1922n07
33. Hms2093m06
34. Perindopril Erbumine [jan]
35. Pharmakon1600-01505212
36. Perindopril Erbumine [vandf]
37. Tox21_303915
38. Bdbm50248096
39. Ccg-39035
40. Nsc758929
41. Perindopril Erbumine [mart.]
42. Perindopril Erbumine [usp-rs]
43. Perindopril Erbumine [who-dd]
44. Perindopril T-butylamine Salt- Bio-x
45. Akos015841351
46. Akos015961912
47. Cs-1904
48. Ks-1243
49. Nsc 758929
50. Perindopril Tert-butylamine [mi]
51. Ncgc00178276-01
52. Ncgc00357164-01
53. 1h-indole-2-carboxylic Acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-, (2s-(1(r*(r*)),2alpha,3abeta,7abeta))-, Compd. With 2-methyl-2-propanamine (1:1)
54. 2-methylpropan-2-amine (2s,3as,7as)-1-(((s)-1-ethoxy-1-oxopentan-2-yl)-l-alanyl)octahydro-1h-indole-2-carboxylate
55. Ac-19078
56. Bp164255
57. Perindopril Erbumine [orange Book]
58. Perindopril Erbumine [usp Monograph]
59. Amlessa Component Perindopril Erbumine
60. Cas-107133-36-8
61. S9490
62. C07707
63. D00624
64. 133p368
65. Perindopril Tert-butylamine [ep Monograph]
66. Sr-05000001835
67. Sr-05000001835-1
68. Q27107642
69. Perindopril Erbumine, United States Pharmacopeia (usp) Reference Standard
70. Perindopril Tert-butylamine, European Pharmacopoeia (ep) Reference Standard
71. Perindopril Erbumine, Pharmaceutical Secondary Standard; Certified Reference Material
72. Perindopril For Peak Identification, European Pharmacopoeia (ep) Reference Standard
73. Perindopril For Stereochemical Purity, European Pharmacopoeia (ep) Reference Standard
74. (2s,3as,7as)-1-{(2s)-2-[(1s)-1-(ethoxycarbonyl)butylamino]propanoyl}octahydro-1h-indole-2-carboxylic Acid--2-methylpropan-2-amine (1/1)
75. (2s,3as,7as)-1-{(s)-2-[(s)-1-(ethoxycarbonyl)butylamino]propanoyl}octahydroindole-2-carboxylic Acid--1,1-dimethylethanamine (1/1)
76. 1h-indole-2-carboxylic Acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-, (2s-(1(r*(r*)),2.alpha.,3a.beta.,7a.beta.))-, Compd. With 2-methyl-2-propanamine (1:1)
77. 1h-indole-2-carboxylic Acid,1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-,(2s,3as,7as)-, Compd. With 2-methyl-2-propanamine (1:1)other Ca Index Names:2-propanamine, 2-methyl-,(2s,3as,7as)-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-1h-indole-2-carboxylate
78. 2-methylpropan-2-amine (2s,3as,7as)-1-((s)-2-(((s)-1-ethoxy-1-oxopentan-2-yl)amino)propanoyl)octahydro-1h-indole-2-carboxylate
79. 2-methylpropan-2-amine (2s,3as,7as)-1-((s)-2-((s)-1-ethoxy-1-oxopentan-2-ylamino)propanoyl)octahydro-1h-indole-2-carboxylate
| Molecular Weight | 441.6 g/mol |
|---|---|
| Molecular Formula | C23H43N3O5 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 9 |
| Exact Mass | 441.32027148 g/mol |
| Monoisotopic Mass | 441.32027148 g/mol |
| Topological Polar Surface Area | 122 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 549 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Aceon |
| PubMed Health | Perindopril (By mouth) |
| Drug Classes | Antihypertensive, Cardiovascular Agent, Renal Protective Agent |
| Drug Label | ACEON (perindopril erbumine) Tablets contain the tert-butylamine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Perindopril erbumine is chemically described as (2S,3S,7S)-1-[(S)-N-[(S)-... |
| Active Ingredient | Perindopril erbumine |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 4mg; 2mg; 8mg |
| Market Status | Prescription |
| Company | Symplmed Pharms |
| 2 of 4 | |
|---|---|
| Drug Name | Perindopril erbumine |
| Drug Label | Perindopril erbumine tablets contain the tert-butylamine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Perindopril erbumine is chemically described as (2S,3S,7S)-1-[(S)-N-[(S)-1-Carboxy-bu... |
| Active Ingredient | Perindopril erbumine |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 8mg; 4mg; 2mg |
| Market Status | Prescription |
| Company | Ani Pharms; Apotex; Aurobindo Pharma; Lupin; Roxane |
| 3 of 4 | |
|---|---|
| Drug Name | Aceon |
| PubMed Health | Perindopril (By mouth) |
| Drug Classes | Antihypertensive, Cardiovascular Agent, Renal Protective Agent |
| Drug Label | ACEON (perindopril erbumine) Tablets contain the tert-butylamine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Perindopril erbumine is chemically described as (2S,3S,7S)-1-[(S)-N-[(S)-... |
| Active Ingredient | Perindopril erbumine |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 4mg; 2mg; 8mg |
| Market Status | Prescription |
| Company | Symplmed Pharms |
| 4 of 4 | |
|---|---|
| Drug Name | Perindopril erbumine |
| Drug Label | Perindopril erbumine tablets contain the tert-butylamine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor. Perindopril erbumine is chemically described as (2S,3S,7S)-1-[(S)-N-[(S)-1-Carboxy-bu... |
| Active Ingredient | Perindopril erbumine |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 8mg; 4mg; 2mg |
| Market Status | Prescription |
| Company | Ani Pharms; Apotex; Aurobindo Pharma; Lupin; Roxane |
Angiotensin-Converting Enzyme Inhibitors
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 2MG
USFDA APPLICATION NUMBER - 20184
DOSAGE - TABLET;ORAL - 4MG
USFDA APPLICATION NUMBER - 20184
DOSAGE - TABLET;ORAL - 8MG
USFDA APPLICATION NUMBER - 20184
Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Direct Compression
Granulation
Lubricants & Glidants
Co-Processed Excipients
Thickeners and Stabilizers
Disintegrants & Superdisintegrants
Controlled & Modified Release
Emulsifying Agents
Coating Systems & Additives
Chewable & Orodispersible Aids
Taste Masking
Film Formers & Plasticizers
API Stability Enhancers
Rheology Modifiers
Parenteral
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
75
PharmaCompass offers a list of Perindopril Erbumine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Perindopril Erbumine manufacturer or Perindopril Erbumine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Perindopril Erbumine manufacturer or Perindopril Erbumine supplier.
PharmaCompass also assists you with knowing the Perindopril Erbumine API Price utilized in the formulation of products. Perindopril Erbumine API Price is not always fixed or binding as the Perindopril Erbumine Price is obtained through a variety of data sources. The Perindopril Erbumine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Covapril manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Covapril, including repackagers and relabelers. The FDA regulates Covapril manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Covapril API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Covapril manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Covapril supplier is an individual or a company that provides Covapril active pharmaceutical ingredient (API) or Covapril finished formulations upon request. The Covapril suppliers may include Covapril API manufacturers, exporters, distributors and traders.
click here to find a list of Covapril suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Covapril DMF (Drug Master File) is a document detailing the whole manufacturing process of Covapril active pharmaceutical ingredient (API) in detail. Different forms of Covapril DMFs exist exist since differing nations have different regulations, such as Covapril USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Covapril DMF submitted to regulatory agencies in the US is known as a USDMF. Covapril USDMF includes data on Covapril's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Covapril USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Covapril suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Covapril Drug Master File in Japan (Covapril JDMF) empowers Covapril API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Covapril JDMF during the approval evaluation for pharmaceutical products. At the time of Covapril JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Covapril suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Covapril Drug Master File in Korea (Covapril KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Covapril. The MFDS reviews the Covapril KDMF as part of the drug registration process and uses the information provided in the Covapril KDMF to evaluate the safety and efficacy of the drug.
After submitting a Covapril KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Covapril API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Covapril suppliers with KDMF on PharmaCompass.
A Covapril CEP of the European Pharmacopoeia monograph is often referred to as a Covapril Certificate of Suitability (COS). The purpose of a Covapril CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Covapril EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Covapril to their clients by showing that a Covapril CEP has been issued for it. The manufacturer submits a Covapril CEP (COS) as part of the market authorization procedure, and it takes on the role of a Covapril CEP holder for the record. Additionally, the data presented in the Covapril CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Covapril DMF.
A Covapril CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Covapril CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Covapril suppliers with CEP (COS) on PharmaCompass.
A Covapril written confirmation (Covapril WC) is an official document issued by a regulatory agency to a Covapril manufacturer, verifying that the manufacturing facility of a Covapril active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Covapril APIs or Covapril finished pharmaceutical products to another nation, regulatory agencies frequently require a Covapril WC (written confirmation) as part of the regulatory process.
click here to find a list of Covapril suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Covapril as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Covapril API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Covapril as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Covapril and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Covapril NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Covapril suppliers with NDC on PharmaCompass.
Covapril Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Covapril GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Covapril GMP manufacturer or Covapril GMP API supplier for your needs.
A Covapril CoA (Certificate of Analysis) is a formal document that attests to Covapril's compliance with Covapril specifications and serves as a tool for batch-level quality control.
Covapril CoA mostly includes findings from lab analyses of a specific batch. For each Covapril CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Covapril may be tested according to a variety of international standards, such as European Pharmacopoeia (Covapril EP), Covapril JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Covapril USP).
